ArticleJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2026
CEACAM7 Expression and DNA Methylation: Prognostic Biomarkers for Lung Adenocarcinoma in African Americans.
Article in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
introductionThe goals of this study were to identify lung cancer biomarkers specific to African Americans (AA) by conducting a genome-wide analysis and to understand the role of these biomarkers in overall survival. MATERIAL AND
methodsAll cancers studied by The Cancer Genome Atlas were queried with the TCGAbiolinks R package (RRID:SCR_017683) for mRNA expression, DNA methylation, and clinical data. Differential expression analysis was performed comparing mRNA expression between AA and Whites. Survival duration differences were studied using the 2-tailed log-rank test. Association with survival was quantified using hazard ratios with 95% confidence intervals with univariate and multivariate Cox proportional hazard models. Spearman's rank correlation analysis was used to identify CpG sites correlated with mRNA expression.
resultsCEACAM7 was the only gene overexpressed among AA compared with Whites with lung adenocarcinoma (LUAD), and its RNA expression was significantly associated with cancer stage, overall survival duration, and mortality risk in AA. DNA methylation on CpG probes cg22895231, cg25465322, cg01656853, cg17659920, and cg07940585 was negatively correlated with CEACAM7 mRNA expression, directly associated with survival duration, and inversely associated with mortality risk in AA with LUAD. Median survival was 37.29 months versus not reached for the high versus low CEACAM7 expression groups. The 1-, 2-, and 5-year survival rates for the high versus low CEACAM7 mRNA expression were 80% versus 100%, 50% versus 100%, and 20% versus 86%, respectively.
conclusionCEACAM7 mRNA expression and its DNA methylation may be associated with overall survival duration and mortality risk among AA with LUAD but not in Whites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.